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Sweet's syndrome is characterized by fever, neutrophilia, and pain-
ful erythematous cutaneous nodules. For this reason, this rare dermato-
logic condition is also called Acute Febrile Neutrophilic Dermatosis.
Classifying by etiology, cases of Sweet's syndrome may be subdivided
into classical or idiopathic Sweet's syndrome, malignancy-associated
Sweet's syndrome (usually hematologic), and drug-induced Sweet's
syndrome (Cohen, 2007).
Drug-induced Sweet's syndrome was ﬁrst described in associa-
tion with trimethoprim-sulfamethoxazole, but is most commonly
associated with granulocyte-colony stimulating factor (ﬁlgastrim)
(Cohen, 2007). Many other drugs including all-trans retinoic acid,
nitrofurantoin, minocycline, hydralazine, furosemide and oral con-
traceptive pills have also been associated with Sweet's syndrome
(Cohen, 2007; Paydas et al., 1993; Walker and Cohen, 1996; Khan
Durani and Jappe, 2002; Gilmour et al., 1995). Topotecan-induced
Sweet's syndrome, however, has never been described in the literature.
Case
Patient is a 37-year old, gravida 3, para 2 with a history of
previously treated melanoma who was undergoing treatment with
topotecan chemotherapy for recurrent stage IIIc low-malignant po-
tential neoplasm of the ovary. Her 28 day treatment cycles included
topotecan infusions on days 1, 8 and 15. She successfully completed⁎ Corresponding author at: University of Michigan Medical Center, Department of
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for cycle #5 was increased from 2.96 mg/m2 to 3.45 mg/m2. She ini-
tiated cycle #5 and received treatments on days 1 and 15 only. It is
unclear why the patient did not present for her day 8 treatment.
The patient subsequently missed the start of cycle #6 and presented
ﬁve days later (nineteen days after her cycle #5, day 15 treatment)
with left eye irritation and an erythematous papular and vesicular
rash on her neck and chest. Vital signs did not demonstrate a fever.
She was diagnosed with dermatitis and conjunctivitis NOS and treat-
ed with 80 mg IV methylprednisolone acetate and sulfacetamide so-
dium ophthalmic solution. Her symptoms improved. Two days later
she started cycle #6 and ﬁnished weekly topotecan treatments on
days 1, 8 and 15. Her dose was increased again from 3.45 mg/m2 to
3.94 mg/m2. Eight days after her cycle #6, day #15 treatment the pa-
tient represented with bilateral eye irritation and rash. She remained
afebrile. She was diagnosed with herpes zoster and treated for 3 days
with acyclovir eye drops without improvement.
The patient then presented to the University of Michigan Emer-
gency Department and was noted to have an extremely pruritic, ery-
thematous, edematous rash around her eyes and covering her eyelids
(Fig. 1). Her sclerae were injected and she complained of a sense of
dry eyes, blurry vision, and diplopia. There were scattered papules
and pustules over the upper forehead and diffusely throughout the
scalp, most prominent on the posterior scalp and nape of the neck,
with signiﬁcant erosion of skin and serous drainage forming a yellow
crust on her hair. Erythematous papules and macules were also noted
on the medial breasts and forearms, some of which excoriated. Approx-
imately four excoriated erythematous papules were noted on the
patient's left forearm and six on the right. There were no abnormalities
of the oral mucosa and ophthalmologic examination was normal. She
was afebrile at this time with a temperature of 36.6 °C. Complete blood
count showed hemoglobin of 13.8 g/dl, platelets of 260,000 and white
blood cell count of 6500 with 51.2% neutrophils and 33.9% lymphocytes.
Creatinine was 0.4 mg/dL and liver function tests were within normal
limits. Erythrocyte sedimentation rate and C-reactive protein were not
obtained. A skin biopsy was performed which is discussed below.
The patient was admitted to the hospital and treated with erythro-
mycin eye ointment, desonide steroid cream for lesions on the face,
ﬂuocinonide 0.05% topical solution for the scalp and clobetasol
0.05% emollient for the upper body lesions. Given the degree of sec-
ondary impetiginization, she was also given a course of cefazolin.
Wound culture subsequently grew Staphylococcus aureus and the an-
tibiotic treatment was changed to clindamycin in accordance with
sensitivities. Signiﬁcant improvement in the patient's eye erythema
Fig. 1. Erythematous, edematous rash around the eyes and covering eyelids. Fig. 3. Numerous interstitial neutrophils with leukocytoclasis. The blood vessels appear
reactive but without evidence of vasculitis. (Hematoxylin–eosin stain, 400).
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tion after two days.
Pathology
Punch biopsy from the left upper back revealed a dense neutro-
philic inﬁltrate within the upper dermis (Fig. 2). The neutrophils
were present diffusely in the interstitium, and demonstrated prominent
leukocytoclasis (nuclear dusts from degenerated neutrophils) (Fig. 3).
Occasional eosinophils were also present. Therewas no evidence of vas-
culitis. The overlying epidermiswasmildly spongiotic, and the papillary
dermis was signiﬁcant for edema. Brown-Hopps and Grocott's methe-
namine silver (GMS) stains were negative for bacterial and fungal or-
ganisms, respectively. Overall, the features are those of neutrophilic
dermatosis, and are most consistent with Sweet's syndrome. The pres-
ence of eosinophils suggests a drug-related etiology.
Discussion
Diagnostic criteria for drug-induced Sweet's syndrome, as outlined by
Walker and Cohen (Walker and Cohen, 1996) includes all ﬁve of the fol-
lowing clinical manifestations: (i) acute onset of painful erythematous
plaques or nodules; (ii) histopathological evidence of a dense neutro-
philic inﬁltrate without evidence of leukocytoclastic vasculitis; (iii)
pyrexia; (iv) a temporal relationship between drug administration andFig. 2. Dense neutrophilic inﬁltrate with associated papillary dermal edema and mild
epidermal spongiosis. (Hematoxylin–eosin stain, 100×).clinical symptoms or a temporally-related recurrence after drug
rechallenge; and (v) resolution of lesions after drug withdrawal or
after treatment with corticosteroids. Our patient meets all of the
above criteria except for pyrexia >38 °C, but this symptommay have re-
solved prior to her presentation for evaluation. Independent of therapeu-
tic intervention, fever typically improves 1–3 days after the offending
drug is stopped (Walker and Cohen, 1996). Additionally, it is certainly
possible that transient, evanescent febrile episodes were missed.
The distribution of lesions in our patient is also typical of drug-
induced Sweet's syndrome, with upper extremities being the most
common location followed by lower extremities, face, trunk and neck
(Walker and Cohen, 1996; Saez et al., 2004). Although less common in
the drug-induced or malignancy-associated subtypes, ocular involve-
ment has also been described in Sweet's syndrome (Cohen, 2007;
Walker and Cohen, 1996).
Neutrophilia is also described as one of four minor ﬁndings fre-
quently present in Sweet's syndrome. Others include: erythrocyte sed-
imentation rate >20 mm/h, elevated C-reactive protein, and >70%
neutrophils (Cohen, 2007). A review of 38 cases of Sweet's syndrome,
including all subtypes, by von den Driesch showed that 20% of cases
had b8000 leukocytes (VondenDriesch, 1994). In the largest case series
of drug-induced Sweet's syndrome, including 49 cases reviewed by
Saez et al., neutrophilia was only documented in 11 cases (22%) (Saez
et al., 2004). Leukocytosis in our patient may have been absent second-
ary to the myelosuppressive effects of topotecan.
Approximately 21% of Sweet's syndrome cases are secondary to
malignancy (Cohen and Kurzrock, 1993), but malignancy is unlikely to
have been the cause in our case. Malignancies associated with Sweet's
syndrome are typically hematologic such as acute myelogenous
leukemia (AML). Although much less common, Sweet's syndrome can
be associated with solid tumors. Typical sites of origin include the geni-
tourinary tract, breast or gastrointestinal tract (Cohen et al., 1993).
There is only one case report of Sweet's syndrome associated with ovar-
ian cancer (Nguyen et al., 1983) but it was not a tumor of lowmalignant
potential as in our case.
Systemic corticosteroids are the gold standard treatment for Sweet's
syndrome. High potency topical steroids have also been found to be ef-
fective (Cohen, 2007). Other less commonly used treatment options in-
clude potassium iodide, dapsone, colchicine or indomethacin. Removal
of the offending drug is often sufﬁcient, especially in cases of Sweet's
Syndrome associatedwith G-CSF treatment when systemic steroids can-
not be used. In these cases the lesions typically clear within 7–21 days
(Saez et al., 2004). The average time for clearing of lesions treated with
systemic corticosteroids is 11 days and those who used topical cortico-
steroids healed within 3–30 days (Walker and Cohen, 1996). Unlike
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induced Sweet's Syndrome almost never recurs unless there is re-
exposure to the offending drug (Cohen, 2007).
Our patient's symptoms improved with IV methylprednisolone and
subsequently recurred with repeat drug exposure. Possible dose depen-
dence has been demonstrated inminocycline-induced Sweet's syndrome
(KhanDurani and Jappe, 2002). The single dose of IVmethylprednisolone
may have decreased the severity of symptoms until the cumulative effect
of the topotecan treatment cycle was realized. The increased dose of
topotecan may also have contributed to the recurrence of symptoms.
Sweet's syndrome is a type of reactive dermatosis or hypersensi-
tivity reaction but the exact pathogenesis remains elusive. Various
bacteria, viruses, and tumor antigens have been postulated as the
causative factor. It is clear that cytokines play a vital role in the devel-
opment of the mucocutaneous lesions characteristically associated
with the disease (Cohen, 2007).
This paper illustrates a case of Sweet's syndrome associated with
topotecan chemotherapy. The patient's presentation with painful er-
ythematous nodules undoubtedly had a temporal relationship to
topotecan administration. Skin punch biopsy illustrated the charac-
teristic dense neutrophilic inﬁltrate without leukocytoclastic vasculi-
tis. Finally, the patient responded well to topical steroids. Sweet's
syndrome should be included in the differential diagnosis of patients
presenting with painful erythematous plaques or nodules following
topotecan chemotherapy. Skin biopsies should be performed when-
ever possible to conﬁrm the diagnosis. Infections often present in a
similar fashion, and therefore, microbial pathology stains and cultures
should also be obtained.Conﬂict of interest statement
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Appendix A. Supplementary data
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.gynor.2013.01.002.
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